BullFrog AI (BFRG) Holdings announced the expansion of its internal sales organization to support accelerated commercialization of the Company’s clinical trial optimization offerings, including its recently launched bfPREP module. The expansion of BullFrog AI’s in-house sales capabilities complements the Company’s recent commercial rollout with Sygnature Discovery, which is focused on selling BullFrog Data Networks target selection solutions to global biopharma clients. By strengthening its direct sales organization, BullFrog AI is positioned to accelerate adoption of its trial-focused platforms, including bfPREP, among pharmaceutical and biotechnology companies.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BFRG:
- Bullfrog AI, Sygnature announces official sales launch of BullFrog networks
- BullFrog AI Holds 2025 Annual Stockholders Meeting
- Bullfrog AI to showcase AI-powered clinical data solutions in Xtalks Webinar
- BullFrog AI Enters $10M Stock Purchase Agreement
- Bullfrog AI provides update on collaboration with Eleison